Prostaglandins inhibit 5-lipoxygenase-activating protein expression and leukotriene B4 production from dendritic cells via an IL-10-dependent mechanism

J Immunol. 2003 Jan 1;170(1):139-46. doi: 10.4049/jimmunol.170.1.139.

Abstract

PGs produced from arachidonic acid by the action of cyclooxygenase enzymes play a pivotal role in the regulation of both inflammatory and immune responses. Because leukotriene B4 (LTB4), a product of 5-lipoxygenase (5-LO) pathway, can exert numerous immunoregulatory and proinflammatory activities, we examined the effects of PGs on LTB4 release from dendritic cells (DC) and from peritoneal macrophages. In concentration-dependent manner, PGE1 and PGE2 inhibited the production of LTB4 from DC, but not from peritoneal macrophage, with an IC50 of 0.04 microM. The same effect was observed with MK-886, a 5-LO-activating protein (FLAP)-specific inhibitor. The decreased release of LTB4 was associated with an enhanced level of IL-10. Furthermore, the inhibition of LTB4 synthesis by PGs was significantly reversed by anti-IL-10, suggesting the involvement of an IL-10-dependent mechanism. Hence, we examined the effects of exogenous IL-10 on the 5-LO pathway. We demonstrate that IL-10 suppresses the production of LTB4 from DC by inhibiting FLAP protein expression without any effect on 5-LO and cytosolic phospholipase A2. Taken together, our results suggest links between DC cyclooxygenase and 5-LO pathways during the inflammatory response, and FLAP is a key target for the PG-induced IL-10-suppressive effects.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 5-Lipoxygenase-Activating Proteins
  • Adjuvants, Immunologic / pharmacology
  • Animals
  • Arachidonate 5-Lipoxygenase / biosynthesis
  • Arachidonate 5-Lipoxygenase / metabolism*
  • Calcimycin / pharmacology
  • Carrier Proteins / antagonists & inhibitors*
  • Carrier Proteins / biosynthesis*
  • Carrier Proteins / physiology
  • Cells, Cultured
  • Cyclooxygenase Inhibitors / pharmacology
  • Cytosol / enzymology
  • Dendritic Cells / drug effects
  • Dendritic Cells / enzymology
  • Dendritic Cells / metabolism*
  • Dinoprostone / pharmacology
  • Eicosanoids / biosynthesis
  • Group IV Phospholipases A2
  • Immune Sera / pharmacology
  • Interleukin-10 / biosynthesis
  • Interleukin-10 / immunology
  • Interleukin-10 / pharmacology
  • Interleukin-10 / physiology*
  • Leukotriene B4 / antagonists & inhibitors*
  • Leukotriene B4 / biosynthesis*
  • Leukotriene B4 / metabolism
  • Leukotriene B4 / pharmacology
  • Macrophages, Peritoneal / drug effects
  • Macrophages, Peritoneal / enzymology
  • Macrophages, Peritoneal / metabolism
  • Membrane Proteins / antagonists & inhibitors*
  • Membrane Proteins / biosynthesis*
  • Membrane Proteins / physiology
  • Mice
  • Mice, Inbred BALB C
  • Nuclear Envelope / drug effects
  • Nuclear Envelope / enzymology
  • Phospholipases A / biosynthesis
  • Phospholipases A / metabolism
  • Phospholipases A2
  • Prostaglandin-Endoperoxide Synthases / biosynthesis
  • Prostaglandin-Endoperoxide Synthases / physiology
  • Prostaglandins / physiology*
  • Protein Transport / drug effects
  • Signal Transduction / drug effects
  • Signal Transduction / immunology

Substances

  • 5-Lipoxygenase-Activating Proteins
  • Adjuvants, Immunologic
  • Alox5ap protein, mouse
  • Carrier Proteins
  • Cyclooxygenase Inhibitors
  • Eicosanoids
  • Immune Sera
  • Membrane Proteins
  • Prostaglandins
  • Interleukin-10
  • Leukotriene B4
  • Calcimycin
  • Arachidonate 5-Lipoxygenase
  • Prostaglandin-Endoperoxide Synthases
  • Phospholipases A
  • Group IV Phospholipases A2
  • Phospholipases A2
  • Dinoprostone